Pfizer investors stand with CEO Read even though he is 0 for 2 on megamergers

Eric Palmer Pfizer CEO Ian Read walked away from its $ 160 billion merger with Allergan this week after U.S. Treasury Department rule changes sucked the value out of its tax inversion ...

FDA not satisfied with Cadila’s efforts to fix warfarin production, even after 15 responses

Eric Palmer Cadila Healthcare last week got out in front of bad news by announcing it had received a warning letter from the FDA for two of its Indian plants but was ...

Novartis CEO stands by emerging markets even as China economy continues to weaken

Eric Palmer China's economy is a mess and other emerging markets are flailing about as well. So what is pharma CEO to do if they have bet big on growth in the EM realm? Keep on ...

Eisai to cut R&D, even as it boosts its sales operation

Eric Palmer Japanese drugmaker Eisai is cutting its R&D operations, with plans to eliminate 130 positions from its facility in Andover, MA, as well as other research centers ...

U.K.’s nod to J&J’s Caelyx comes even as shortages expected

Eric Palmer The U.K. drug price watchdog today gave Johnson & Johnson's Caelyx the distinction of being one of only two drugs it believes should be funded by the National Health ...

GSK sends contingent to China, even as country prevents one exec from leaving

Eric Palmer Given that China is preventing a top GlaxoSmithKline exec from leaving the country as it investigates alleged bribery in the country, it seems risky to send more of his ...

Even if Actavis buy fails, Valeant looks ready for bigger deals

Tracy Staton Valeant ($ VRX) CEO J. Michael Pearson hasn't made a secret of his ambitions. He wants to be within spitting distance of Big Pharma. Numbers-wise, that means he's ...
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS